NCT07103291 Effects of Isocapnic Respiratory Muscle Endurance Training in Healthy Adults
| NCT ID | NCT07103291 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Healthy Adults |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2025-08-04 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2025-08-04 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Respiratory muscle training (RMT) strengthens breathing muscles and may improve exercise performance and reduce breathlessness. However, different training methods and devices create controversy in the field. Two main types of RMT exist: inspiratory muscle training (IMT) and respiratory endurance training, like voluntary isocapnic hyperpnea (VIH). While IMT is well-studied, the impact of VIH on breathlessness remains unclear. This study will use the Canadian-developed BreathWayBetter device to examine how 5 weeks of VIH affects breathing discomfort and muscle function. Findings may help personalize RMT for athletes and clinical patients, improving respiratory care and exercise tolerance.
Eligibility Criteria
Inclusion Criteria: * 18-55 years of age (inclusive) * Male or Female (biological sex) * Body mass index greater than 18 or less than 30 kg/m2 * Normal pulmonary function: FEV1/FVC \> 0.70 and FEV1 ≥ 80% * Able to read and understand English * Regularly trains and/or competes at a regional, national, or international level as a road cyclist or triathlete * Access to a device with the capability to download the Isocapnic app (Apple IOS or Google Play/Android) or the ability to use the Web Based application. Exclusion Criteria: * Currently smoke, vape, or use cannabis, or have a history of frequent smoking, vaping or cannabis use * History of, or current symptoms of cardiopulmonary (i.e., lung and/or heart) disease (excluding controlled asthma) * Heart problem; a serious infection within the body; a neuromuscular (nerve to muscle) or musculoskeletal (muscle, ligament and/or bone) disorder; or other health problem that will be made worse with exercise testing * Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g. a problem with the heart or lungs, muscle or bone injury, a serious infection) * Currently pregnant * Required to read and understand English due to the nature of the consent form and study materials, including questionnaires and training instructions, which are only available in English.
Contact & Investigator
Jordan Guenette, PhD
PRINCIPAL INVESTIGATOR
University of British Columbia
Frequently Asked Questions
Who can join the NCT07103291 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Healthy Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07103291 currently recruiting?
Yes, NCT07103291 is actively recruiting participants. Contact the research team at Olivia.Ferguson@hli.ubc.ca for enrollment information.
Where is the NCT07103291 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT07103291 clinical trial?
NCT07103291 is sponsored by University of British Columbia. The principal investigator is Jordan Guenette, PhD at University of British Columbia. The trial plans to enroll 32 participants.